Evaluation of BRAF v600 mutation by single strand conformation polymorphism-PCR (SSCP-PCR) in patients with interstitial lung disease

Abstract

Abstract Background: Many studies demonstrating a high predominance of pulmonary disease among individuals with interstitial lung disease (ILD), genomic examinations have recognized and initiated mutations in proto-oncogene B-Raf (BRAF) among patients with lung malignant growth. To support our hypothesis of being ILD could show a more vital event for framing into bronchogenic threat BRAFV600E change was examined. Objectives: To inquire about the frequency of BRAF (V600E) mutation in ILD with the possible evaluation of the presence of BRAF V600 mutation and such parameters as patient’s age, gender, and histopathological type. Materials and Methods: From January 2017 to April 2019, a review study was led in a few confidential labs and the Teeba respiratory focus in Hilla city, Babylon region. Sixty patients with interstitial lung issues’ clarifying data were recuperated, formalin-fixed paraffin-embedded (FFPE) tissue portions were furthermore collected, all of the results were surveyed by three expert histopathologists, and the last attestation of the examination was done. Equivalent number (60) of healthy lung tissues were also involved and used as control tests for polymerase chain reaction review. Results: Only two (3.3%) of ILD tests harbored BRAF V600E change, all of them were between 41 and 50 years and were the usual interstitial pneumonitis (UIP) type. Conclusions: BRAF V600E mutation likely could be identified in ILD especially UIP. Prognosis of such patients with mutated BRAF gene should be observed.